Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James

Raymond James upgraded shares of Dyne Therapeutics (NASDAQ:DYN) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.

A number of other analysts have also recently weighed in on DYN. Oppenheimer reiterated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Piper Sandler reiterated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Royal Bank of Canada initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $50.42.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $25.73 on Thursday. Dyne Therapeutics has a 1-year low of $11.51 and a 1-year high of $47.45. The company has a market capitalization of $2.62 billion, a PE ratio of -7.23 and a beta of 1.09. The business has a 50-day moving average of $30.39 and a 200-day moving average of $35.23.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts expect that Dyne Therapeutics will post -3.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the sale, the chief operating officer now owns 131,636 shares of the company’s stock, valued at $4,529,594.76. The trade was a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 180,046 shares of company stock worth $6,300,265 over the last ninety days. 20.77% of the stock is currently owned by company insiders.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in Dyne Therapeutics during the third quarter worth $62,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.